0001209191-19-041552.txt : 20190709 0001209191-19-041552.hdr.sgml : 20190709 20190709162001 ACCESSION NUMBER: 0001209191-19-041552 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190705 FILED AS OF DATE: 20190709 DATE AS OF CHANGE: 20190709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davidson David CENTRAL INDEX KEY: 0001578696 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 19947431 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-07-05 0 0001293971 bluebird bio, Inc. BLUE 0001578696 Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 2019-07-05 4 M 0 7330 50.51 A 38946 D Common Stock 2019-07-05 4 M 0 330 5.5004 A 39276 D Common Stock 2019-07-05 4 S 0 2828 128.2762 D 36448 D Common Stock 2019-07-05 4 S 0 832 129.3168 D 35616 D Common Stock 2019-07-05 4 S 0 3300 130.0464 D 32316 D Common Stock 2019-07-05 4 S 0 700 131.7686 D 31616 D Stock Option (right to buy) 50.51 2019-07-05 4 M 0 7330 0.00 D 2026-03-01 Common Stock 7330 19745 D Stock Option (right to buy) 5.5004 2019-07-05 4 M 0 330 0.00 D 2023-01-16 Common Stock 330 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019. The range in prices for the transaction reported on this line was $127.92 to $128.89. The average weighted price was $128.2762. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $128.93 to $129.83. The average weighted price was $129.3168. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $129.94 to $130.91. The average weighted price was $130.0464. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $131.26 to $132.23. The average weighted price was $131.7686. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter. This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013 and April 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014 and April 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years. /s/ Jason F. Cole, Attorney-in-Fact 2019-07-09